TREATMENT OF GASTRIC CANCER FOR SURVIVAL-STRATEGIES IN THE USA AND JAPAN

Lisa Baddi; Mary Mulcahy; Al Benson III

doi:10.4993/acrt1992.11.15

著者情報

キーワード: Adenocarcinoma, bryostatin, cis-platin, docetaxel, drug toxicity, 5-FU, G17DT, gastric cancer, irinotecan, LV5FU2, marimastat, phase II and III trials, survival, V325

ジャーナルフリー

2003 年 11 巻 1-2 号 p. 15-30

DOI https://doi.org/10.4993/acrt1992.11.15

詳細

抄録

Chemotherapy has been shown to benefit patients with gastric cancer. The most effective regimen remains controversial. A recent large randomized clinical trial has demonstrated an advantage with the addition of docetaxel to 5-fluorouracil and cisplatin. New agents are being incorporated into the treatment of gastric cancer to maximize efficacy with minimal additional toxicity. Future clinical trials will explore the use of new agents as well as genetic polymorphisms that may influence drug metabolism and efficacy.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）